Zileuton, 5-lipoxygenase blocker, modulates acute inflammatory response in Nile tilapia

Pharmacological control of leukotriene biosynthesis is well established in mammals, but its translational value for teleost inflammation remains unclear. We evaluated oral 5-lipoxygenase (5-LOX) inhibition with zileuton in Nile tilapia challenged with a bacterin of A. hydrophila to induce acute aerocystitis. Fish received vehicle or zileuton (2.25 or 4.50 mg/kg) before challenge. Outcomes were assessed at 6, 24, and 48 h post-inoculation (hpi) to investigate cellular profiles in exudates and blood, reactive oxygen species (ROS), acute-phase proteins (APPs), and the formation of splenic melano-macrophage centers (MMCs). Zileuton significantly reduced exudate granulocytes and thrombocytes at 6 hpi and macrophages at 24 hpi. Systemically, treatment attenuated transient peaks in neutrophils and lymphocytes (6 hpi) and thrombocytes (24-48 hpi). We observed correlations between lower ROS production and reduced blood neutrophil counts and macrophages in the exudate, suggesting a restrained oxidative burst. Zileuton down-modulated positive APPs (ceruloplasmin, complement C3, α<sub>2</sub>-macroglobulin, haptoglobin) in time- and dose-dependent patterns, while negative APPs (albumin, transferrin) and apolipoprotein A1 showed no consistent change. Histology revealed MMCs enlargement/remodeling with bacterin that was tempered by zileuton. The anti-inflammatory response was dose-dependent, since fish treated with 4.50 mg/kg were more effective than 2.25 mg/kg. Tilapia receiving 4.50 mg/kg of zileuton exhibited a pronounced decrease in inflammatory cell accumulation in the exudate (granulocytes, lymphocytes, and macrophages), reduced ROS production, stronger suppression of positive acute-phase proteins (notably ceruloplasmin, complement C3, and haptoglobin), and more evident remodeling of splenic MMCs. No clinical adverse effects were observed. To our knowledge, this is the first demonstration in fish that oral 5-LOX inhibition by zileuton mitigates acute inflammatory reaction, and underscores leukotriene pathway as a promising lever for improving fish health outcomes.

Authors

Institutions

Publication Details

Journal
Developmental & Comparative Immunology
Published
2026-03-24
DOI
https://doi.org/10.1016/j.dci.2026.105595
Primary Topic
Aquaculture disease management and microbiota
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Zileuton, 5-lipoxygenase blocker, modulates acute inflammatory response in Nile tilapia

Gabriel Conde, Luiz Arthur Malta Pereira, Mayumi Fernanda Aracati, Camila Carlino-Costa et al.
Developmental & Comparative Immunology
Aquaculture disease management and microbiota
article

Zileuton, 5-lipoxygenase blocker, modulates acute inflammatory response in Nile tilapia

Gabriel Conde, Luiz Arthur Malta Pereira, Mayumi Fernanda Aracati, Camila Carlino-Costa, Letícia Franchin Rodrigues, Marco Antonio de Andrade Belo, Patrícia Bianca Clissa, Susana Luporini de Oliveira
article en

Abstract

Pharmacological control of leukotriene biosynthesis is well established in mammals, but its translational value for teleost inflammation remains unclear. We evaluated oral 5-lipoxygenase (5-LOX) inhibition with zileuton in Nile tilapia challenged with a bacterin of A. hydrophila to induce acute aerocystitis. Fish received vehicle or zileuton (2.25 or 4.50 mg/kg) before challenge. Outcomes were assessed at 6, 24, and 48 h post-inoculation (hpi) to investigate cellular profiles in exudates and blood, reactive oxygen species (ROS), acute-phase proteins (APPs), and the formation of splenic melano-macrophage centers (MMCs). Zileuton significantly reduced exudate granulocytes and thrombocytes at 6 hpi and macrophages at 24 hpi. Systemically, treatment attenuated transient peaks in neutrophils and lymphocytes (6 hpi) and thrombocytes (24-48 hpi). We observed correlations between lower ROS production and reduced blood neutrophil counts and macrophages in the exudate, suggesting a restrained oxidative burst. Zileuton down-modulated positive APPs (ceruloplasmin, complement C3, α<sub>2</sub>-macroglobulin, haptoglobin) in time- and dose-dependent patterns, while negative APPs (albumin, transferrin) and apolipoprotein A1 showed no consistent change. Histology revealed MMCs enlargement/remodeling with bacterin that was tempered by zileuton. The anti-inflammatory response was dose-dependent, since fish treated with 4.50 mg/kg were more effective than 2.25 mg/kg. Tilapia receiving 4.50 mg/kg of zileuton exhibited a pronounced decrease in inflammatory cell accumulation in the exudate (granulocytes, lymphocytes, and macrophages), reduced ROS production, stronger suppression of positive acute-phase proteins (notably ceruloplasmin, complement C3, and haptoglobin), and more evident remodeling of splenic MMCs. No clinical adverse effects were observed. To our knowledge, this is the first demonstration in fish that oral 5-LOX inhibition by zileuton mitigates acute inflammatory reaction, and underscores leukotriene pathway as a promising lever for improving fish health outcomes.

Developmental & Comparative ImmunologyVol. 178
Instituto Butantan (BR), Universidade Brasil (BR), Núcleo de Pesquisas Aplicadas (Brazil) (BR), Centro Universitário de Araraquara (BR)
Openalex Percentile: Top 12%
Aquaculture disease management and microbiota
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.